January 18, 2022

CMS Decision on Alzheimer’s Drug Coverage

About This Episode

The Centers for Medicare and Medicaid Services (CMS), the federal health insurance program for people 65 plus, announced its decision to deny covering Biogen’s Aduhelm and all future anti-amyloid treatments under what is known as a Coverage with Evidence Development (CED).  What does this first-round decision mean? 

BrainStorm host, Meryl Comer, and guest, Stephanie Monroe, Executive Director of AfricanAmericansAgainstAlzheimer's and Co-Director of the Center for Brain Health Equity discuss the underlying issues that she calls discriminatory, particularly for communities of color.  

Russ Paulsen, Chief Operating Officer at UsAgainstAlzheimer’s, offers a statement on why UsAgainstAlzheimer’s opposes the CMS decision and provides a statement explaining what this means for those living with Alzheimer’s. 

The proposed National Coverage Determination is open to public comment for 30 days (until Feb 9). A final decision will be announced in April. 

BrainStorm Feed

120

The Financial Toll of Caregiving with Ken and Maddy Dychtwald

It is time to treat caregiving as a societal issue rather than a private family matter. More than 32 million Americans are financial caregivers for

LISTEN NOW
119

The Fine Print on Your Prescriptions: What Families Need to Know About Medicare Part D

You picked a Medicare drug plan in December. Then in January, the pharmacist tells you your medication isn’t covered, or that it needs approval first

LISTEN NOW
118

Risky Business: The Costliest Assumptions for Medicare Families

In part one of BrainStorm’s look at Medicare open enrollment, host Meryl Comer talks with Alison Schneider, Director of Market Access Policy and Strategy at

LISTEN NOW